logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins

Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins

04/23/20, 11:31 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svglexington
Money raised
$63 million
Industry
biotechnology
Round Type
series b
Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced today that it has completed a $63 million Series B financing. The Series B was led by EcoR1 Capital with participation by GV, AbbVie Ventures, The Mark Foundation for Cancer Research, NS Investment and Droia Ventures as well as existing investors, Atlas Venture and The Column Group.

Company Info

Company
Accent Therapeutics
Location
lexington, massachusetts, united states
Additional Info
Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Company news

Tue, 23 Jan 2024 08:00:00 GMT

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies - PR Newswire

Thu, 12 Dec 2024 08:00:00 GMT

The Escalator: Biogen, Accent Therapeutics, Xira Therapeutics and more - MM+M Online

Mon, 18 Oct 2021 07:00:00 GMT

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3 - Business Wire

Thu, 24 Oct 2024 07:00:00 GMT

Accent Therapeutics Announces FDA Clearance of IND Application for ATX-559, a First-In-Class Oral DHX9 Inhibitor - PR Newswire

Mon, 08 Apr 2024 07:00:00 GMT

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting - PR Newswire

Fri, 18 May 2018 07:00:00 GMT

Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins - Business Wire

Wed, 11 Dec 2024 08:00:00 GMT

Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition - PR Newswire

Thu, 21 Mar 2024 07:00:00 GMT

Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American Association for Cancer Research (AACR) Annual Meeting 2024 - PR Newswire

Tue, 10 Oct 2023 07:00:00 GMT

Accent Therapeutics Unveils XRN1 Program and Provides Pipeline Update with Presentations at 35th AACR-NCI-EORTC Symposium - PR Newswire

Sun, 16 Apr 2023 07:00:00 GMT

Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023 - PR Newswire

G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.

Related people

JH

SH

SH

SH

Sign up to get related executive contact information